Research location
Ottignies
Brabant Wallon, Belgium
Advertisement
Research activity in Ottignies
Brabant Wallon, BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ottignies
8 linked trials · page 1 of 1A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerNCT03241810 · 2017-08-15 · 1 site observation
TERMINATED
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · 2015-08-24 · 1 site observation
COMPLETED
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)NCT01942135 · 2013-09-26 · 1 site observation
COMPLETED
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCNCT01798485 · 2013-04-01 · 1 site observation
TERMINATED
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL StudyNCT01272128 · 2012-12-01 · 1 site observation
COMPLETED
Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic CancerNCT00405210 · 2006-09-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic CancerNCT00541281 · 2003-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.